ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0808

SARS-CoV-2 Infection in the Early Post-Transplant Period After a Living Donor Kidney Transplant

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Shingare, Ashay, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
  • Bahadur, Madan, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
  • Chaudhari, Chandan Laxman, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
  • Ganvir, Pankaj Gulabrao, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
  • Garudkar, Sharad Ambadas, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
  • Mehta, Shaurya, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
  • Shah, Harsh Paresh, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
  • Waghmare, Irawati Rajiv, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
  • Colaco, Neville, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
Introduction

Coronavirus disease 2019 (COVID-19) pandemic presented multiple challenges for living and deceased donor kidney transplant programs with the likelihood of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the course of COVID-19 and immunosuppression within 3 months of living donor kidney transplant (LDKT) which has not been described previously.

Case Description

Three LDKT recipients developed COVID-19 in the early post-transplant period and were detected positive for SARS-CoV-2 at day 7, day 19 and 2 months post-transplant. Patients 1 and 2 had received 1 mg/kg of anti-thymocyte globulin (ATG) as induction and patient 3 had received no induction at the time of transplant. Patients 1 and 2 had minimal symptoms at diagnosis, whereas patient 3 had high grade fever, cough and shortness of breath. All 3 patients had lymphopenia at diagnosis and none required supplemental oxygen or intensive care unit monitoring. All 3 patients received azithromycin and hydroxychloroquine. Mycophenolate mofetil dose was reduced in patient 1 and was stopped in patients 2 and 3. Patient 3 developed acute kidney injury with a peak serum creatinine of 2.4 mg/dL, whereas other 2 patients did not develop kidney allograft dysfunction. All 3 patients recovered from SARS-CoV-2 infection with normal renal function at discharge.

Discussion

Limited experience of SARS-CoV-2 infection in early post-transplant period is available in deceased donor kidney transplant (DDKT) with serious morbidity and mortality implications. Lymphopenia described in patients with severe illness due to SARS-CoV-2 can be aggravated by recently used higher dose of lymphocyte depleting agent, especially to cover for delayed graft function in DDKT. As compared to previously reported cases of DDKT, our relatively young recipients of LDKT had a milder course, minimal complications and recovered from SARS-CoV-2 infection. We suggest consideration of recipient age, pretransplant isolation and using induction agent basiliximab or lower dose of ATG for a LDKT program during COVID-19 pandemic.